BIIB

Biogen Idec Inc. Press Releases

$325.7683
*  
5.0417
1.52%
Get BIIB Alerts
*Delayed - data as of Oct. 1, 2014 10:07 ET  -  Find a broker to begin trading BIIB now
Exchange: NASDAQ
Industry: Health Care
Community Rating:
View:    BIIB Real Time
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save stocks for next time
Viewing
Filtered By
Ordered By

Biogen Idec To Report Third Quarter 2014 Financial Results on October 22, 2014
9/25/2014 5:34:00 PM - Business Wire

Biogen Idec Named Global Biotechnology Industry Leader on Dow Jones Sustainability World Index
9/23/2014 8:00:00 AM - Business Wire

Olivier Danos Joins Biogen Idec as Senior Vice President, Gene Therapy
9/23/2014 7:00:00 AM - Business Wire

Detailed Results from Biogen Idec and AbbVie’s Pivotal Phase 3 Decide Study Further Define the Efficacy and Safety Profile of ZINBRYTA™ (Daclizumab High-Yield Process)
9/12/2014 7:30:00 AM - Business Wire

New Data from ENDORSE Show Positive Results Continued over Five Years with TECFIDERA® (Dimethyl Fumarate) in a Wide Range of Multiple Sclerosis Patients
9/11/2014 7:30:00 AM - Business Wire

PLEGRIDY™ (Peginterferon Beta-1a) Two-Year Data Confirm Maintenance of Efficacy and Safety in Multiple Sclerosis Patients
9/11/2014 7:30:00 AM - Business Wire

New International Survey Finds MS Patients and Neurologists View Communication Positively, Yet Struggle to Discuss Key MS Symptoms
9/10/2014 7:00:00 AM - Business Wire

RBCC Explores Novel Uses for New Naltrexone Delivery Protocols
9/4/2014 5:00:00 AM - Business Wire

Biogen Idec Data at Joint ACTRIMS-ECTRIMS Meeting Highlight Robust Multiple Sclerosis Portfolio and Commitment to Advancing Patient Care
9/3/2014 8:00:00 AM - Business Wire

Biogen Idec to Present at the Morgan Stanley Global Healthcare Conference 2014
9/2/2014 4:01:00 PM - Business Wire

Biogen Idec in Panel at the Citi 9th Annual Biotech Conference
8/26/2014 4:01:00 PM - Business Wire

Donald Johns Joins Biogen Idec to Lead ALS Innovation Hub
8/26/2014 8:00:00 AM - Business Wire

Biogen Idec Names Adriana Karaboutis EVP, Technology and Business Solutions
8/21/2014 7:00:00 AM - Business Wire

Biogen Idec’s PLEGRIDY™(Peginterferon Beta-1a) Approved in the US for the Treatment of Multiple Sclerosis
8/15/2014 6:44:00 PM - Business Wire

Regulus Enters Into New Collaboration Agreement with Biogen Idec to Identify microRNA Biomarkers in Multiple Sclerosis
8/5/2014 8:00:00 AM - PR Newswire

RBCC 3D Bioprinting Partner Awarded Prestigious Grant
7/31/2014 6:54:00 AM - Business Wire

PLEGRIDY™ (Peginterferon beta-1a) Approved in the European Union for the Treatment of Multiple Sclerosis
7/23/2014 11:41:00 AM - Business Wire

Biogen Idec Second Quarter 2014 Revenues Increase 40% to $2.4 Billion; Company Raises Financial Guidance for the Year
7/23/2014 6:45:00 AM - Business Wire

Biogen Idec and Yahoo Health Spotlight Visionaries Whose Work Benefits People with Multiple Sclerosis (MS)
7/16/2014 8:00:00 AM - Business Wire

Biotech Equities under the Scanner -- Research on Alexion Pharma, InterMune, Cytokinetics, and Biogen Idec
7/7/2014 5:55:00 AM - PR Newswire